flow trial semaglutide kidney outcomes 2024 nejm hazard ratio clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators 2. dr. Nanang - New

Physicians also consider overall health status, medication adherence history, and realistic treatment expectations

Its not because of the weight loss, its because their metabolic health has improved and inflammation has been suppressed

Until then, it will be important for clinicians and doctors to screen for these disorders before prescribing these medications

It has been investigated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) program, which showed significant reductions in glycated hemoglobin (A1c) and body weight (BW) compared to placebo or other treatments [7,8,9,10,11,12,13,14]

Temperature and pH are the primary drivers of hydrolysis rate

So, weight loss or something more